David Bardey, Manuel Fernandez, and Alexis Gravel, “Coronavirus and Social Distancing: Do Non-Pharmaceutical-Interventions Work (at least) in the Short Run?”, TSE Working Paper, n. 21-1189, February 2021.
James K. Hammitt, and Nicolas Treich, “Fatality Risk Regulation”, TSE Working Paper, n. 21-1177, January 2021.
James K. Hammitt, “Valuing mortality risk in the time of covid-19”, TSE Working Paper, n. 20-1115, June 2020.
James K. Hammitt, “Accounting for the distribution of benefits & costs in benefit-cost analysis”, TSE Working Paper, n. 20-1116, June 2020.
Christian Gollier, “If the objective is herd immunity, on whom should it be built?”, Covid Economics, n. 16, May 2020, pp. 98–114.
Christian Gollier, and Olivier Gossner, “Group testing against Covid-19”, Covid Economics, n. 1, n. 2, April 2020, pp. 32–42.
Pierre Dubois, Paulo Albuquerque, Oliver Allais, Céline Bonnet, Patrice Bertail, P. Compris, Saadi Lahlou, Nathalie Rigal, Bernard Ruffieux, and Pierre Chandon, “Effects of front-of-pack labels on the nutritional quality of supermarket food purchases: evidence from a large-scale randomized controlled trial”, TSE Working Paper, n. 20-1088, April 2020.
Martin Boyer, Philippe De Donder, Claude Fluet, Marie-Louise Leroux, and Pierre-Carl Michaud, “Long-Term Care Insurance: Information Frictions and Selection”, TSE Working Paper, n. 19-1034, September 2019.
David Bardey, and Philippe De Donder, “A Welfare Analysis of Genetic Testing in Health Insurance Markets with Adverse Selection and Prevention”, TSE Working Paper, n. 19-1035, September 2019, revised January 22, 2024.
Pierre Dubois, and Morten Saethre, “On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector”, TSE Working Paper, n. 18-883, January 2018, revised March 2020.